Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Reverb Therapeutics

Request full access

Bispecific antibodies redirecting endogenous cytokines for therapy

Vancouver, CanadaFounded 2022Biotech & Life Sciences

About Reverb Therapeutics

Reverb Therapeutics is a preclinical-stage biotechnology company developing bispecific antibodies to treat diseases by harnessing the body's own immune system. Founded in 2023 by CEO David de Graaf and Chief Scientific Officer Surjit Dixit, the Vancouver-based startup emerged from Amplitude Ventures' Pre-Amp venture studio program. The co-founders bring extensive experience in biologics discovery and development; de Graaf is a serial biopharma entrepreneur, while Dixit was instrumental in developing Zymeworks' Azymetric™ bispecific platform.

The company's core technology is the Amplify•R™ platform, which engineers bispecific antibodies to capture the body's naturally occurring cytokines and concentrate them at specific sites, such as tumors or areas of autoimmune activity. This approach is designed to amplify the immune system's natural signaling locally, avoiding the systemic toxicity, immunogenicity, and manufacturing complexities often associated with administering engineered, external (exogenous) cytokines. The platform combines antibody engineering with data-driven modeling and is modular, allowing for rapid pipeline development across various diseases.

Reverb's business model is focused on advancing its proprietary drug pipeline through preclinical and clinical development. Its initial therapeutic areas are cancer and autoimmune diseases. The lead program, AMP01, uses this technology to block a protein that suppresses immune response while delivering another that activates cancer-fighting T-cells. Preclinical in-vivo studies have demonstrated proof-of-concept, showing the platform's ability to shrink tumors by redirecting these internal cytokines. In February 2025, Reverb Therapeutics announced the closing of a $12 million USD seed financing round led by founding investor Amplitude Ventures, with participation from the Myeloma Investment Fund, KdT Ventures, Finchley Healthcare Ventures, and others, to advance its lead programs to the candidate stage.

Source: Dealroom company data

At a glance

Status
Operational
Employees
20
Open positions
None listed
Dealroom signal
75.4/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Oncology, Drug Development, Antibodies, DT and LS, science-based

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SEED✓Equity / VC Feb 2025 $12M $48M KdT Ventures · Myeloma Investment Fund · InBC Investment · Amplitude Ventures ↗
SEEDEquity / VC Nov 2023 $0 — Amplitude Ventures · Myeloma Investment Fund ↗
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Reverb Therapeutics website traffic

Latest recorded traffic for Reverb Therapeutics is 120 monthly website visits, down 69.2% over the last three months. Reverb Therapeutics's team grew 300% over the past year.

Latest monthly visits120 3-month web change-69.2% 1-year team growth+300%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Reverb Therapeutics in the Vancouver ecosystem

Live from Dealroom

The Reverb Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed6 investors entered at this stage

  • Amplitude Ventures
  • Myeloma Investment Fund
  • KdT Ventures
  • InBC Investment
  • Seido Capital
  • Finchley Healthcare Ventures
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States52.9%
🇨🇦 Canada47.1%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Reverb Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Reverb Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.